The effectiveness and security of anti-MUC1 CAR-T cell therapy combined with PD-1 deletion are being evaluated in Phase I/II clinical trial in advanced NSCLC patients (NCT03525782) [164]. This evidence concerns the gene RPL17 and non-small cell lung carcinoma.